Literature DB >> 20225922

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.

Michael E Sughrue1, Nader Sanai, Gopal Shangari, Andrew T Parsa, Mitchel S Berger, Michael W McDermott.   

Abstract

OBJECT: Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions. The authors present the largest case series to date dealing with these tumors, providing analysis of 63 patients.
METHODS: The authors identified all patients undergoing resection of WHO Grade III tumors at their institution over a 16-year period. They analyzed clinical data from these patients, and performed Kaplan-Meier and Cox regression analyses to determine the impact of different clinical characteristics and different treatment modalities on survival following initial and repeat surgery for these lesions.
RESULTS: Sixty-three patients met inclusion criteria and were analyzed further. The median clinical follow-up time was 5 years (range 1-22 years). The 2-, 5-, and 10-year overall survival rates following initial operation were 82, 61, and 40%, respectively. Kaplan-Meier analysis demonstrated a marked survival benefit with repeat operation (53 vs 25 months, p = 0.02). Interestingly, patients treated with near-total resection experienced improved overall survival when compared with patients treated with gross-total resection at initial (p = 0.035) and repeat operations (p = 0.005). Twelve (19%) of 63 patients experienced significant neurological morbidity referable to the resection of their tumors.
CONCLUSIONS: Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk.

Entities:  

Mesh:

Year:  2010        PMID: 20225922     DOI: 10.3171/2010.1.JNS091114

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  38 in total

1.  Stereotactic radiation therapy for skull base recurrences: Is a salvage approach still possible?

Authors:  Marco Krengli; Giuseppina Apicella; Letizia Deantonio; Marina Paolini; Laura Masini
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-04

2.  De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.

Authors:  Brett J Theeler
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

4.  Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Authors:  Amber J Giles; Shuyu Hao; Michelle Padget; Hua Song; Wei Zhang; John Lynes; Victoria Sanchez; Yang Liu; Jinkyu Jung; Xiaoyu Cao; Rika Fujii; Randy Jensen; David Gillespie; Jeffrey Schlom; Mark R Gilbert; Edjah K Nduom; Chunzhang Yang; John H Lee; Patrick Soon-Shiong; James W Hodge; Deric M Park
Journal:  JCI Insight       Date:  2019-10-17

Review 5.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

6.  Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.

Authors:  Matthieu Peyre; Marc Zanello; Karima Mokhtari; Anne-Laure Boch; Laurent Capelle; Alexandre Carpentier; Stephane Clemenceau; Carine Karachi; Soledad Navarro; Aurelien Nouet; Vincent Reina; Charles-Ambroise Valery; Marc Sanson; Philippe Cornu; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

Review 7.  A review of malignant meningiomas: diagnosis, characteristics, and treatment.

Authors:  Simon Hanft; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

Review 8.  Multimodality Therapy of Patients with Refractory Meningiomas.

Authors:  Haroon Ahmad; David Schiff
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

9.  Management of meningeal neoplasms: meningiomas and hemangiopericytomas.

Authors:  Zanetta Lamar; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2011-09

10.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.